Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma
Yawen Dong, V. Podrascanin, Zhihao Li, Jonas Santol, Markus Ammann, Lionel Aurelien Kankeu Fonkoua, Rondell P. Graham, Caitlin B. Conboy, Nguyen H. Tran, Susanne G Warner, Rory L. Smoot, Patrick P Starlinger
Topics & Concepts
MedicineSurgical oncologyNeoadjuvant therapyTolerabilityGemcitabineCisplatinInternal medicineResponse Evaluation Criteria in Solid TumorsOncologySurgeryChemotherapyProgressive diseaseAdverse effectCancerBreast cancerCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersGastric Cancer Management and Outcomes